2022-2026 Bahrain Tumor Markers Diagnostic Testing Market Assessment-Oncogenes, Biomarkers , GFs, CSFs, Hormones, Stains, Lymphokines-Competitive Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

July 2022 | | ID: 277A4558EC5EEN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

The report is available by section, and can be customized to specific information needs and budget.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contents

I. INTRODUCTION

II. MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

  1. Introduction
  2. Cancer Diagnostic Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27.29
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembrionic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26. Biochemical Cancer Diagnostics
  27. Oncogenes
    Abl/abl-bcr
    AIB1
    BCL-2
    BRCA1
    CD44
    C-fos
    C-myb
    C-myc
    CYP-17
    Erb-B
    HPC1
    N-myc
    P40
    P51
    P53
    PIK3CA
    PTI-1
    Ras
    Reg
    Sis
    Src and others
  28. Polypeptide Growth Factors
    Basic Fibroblast Growth Factor
    Beta-TGF
    Cachectin (TNT)
    Calmodulin
    ECFR
    Nerve Growth Factor (NGF)
    Epidermal Growth Factor (EGF)
    Ornithine Decarboxylase
    Transferrin
    Transforming Growth Factor-Alpha
  29. Ectopic Hormones
  30. Colony Stimulating Factors
  31. Lymphokines
    Alpha-Interferon
    B Cell Growth Factors
    B Cell Growth Factor (BCGF)
    Gamma-Interferon
    Interleukin-1 (IL-1)
    Macrophage Activating Factor
  32. Immunohistochemical Stains
  33. Emerging Cancer Diagnostics
    N-Acetylglucosamine
    Actin
    Alpha-Actin
    Antineuronal Antibodies
    7B2
    B72.3
    Bax
    BCD-F9
    BLCA-4
    Blood Group Antigens A,B,H
    CA
    CA 72-4/TAG-72
    CA
    CA-242
    CA-549
    CAM
    CAR-3
    Cathepsin-D
    Chromogranin A and B
    Cluster 1 Antigen
    Cluster-5/5A Antigen
    CTA
    CU18
    DR-70
    DU-PAN-2
    Endometrial Bleeding Associated Factor
    Endostatin
    Epithelial Membrane Antigen
    Feulgen Hydrolysis
    Fibronectin
    FSH
    (1->3)-L-fucosyltransferase
    Gastrin-Releasing Peptide (GRP)
    GDCFP-15
    Glucagon
    Glycoamines
    H23
    Her-2
    Human Carcinoma Antigen
    HPA
    HSP27
    Intermediate Filaments
    Cytokeratins/CK18/Cyfra 21-1
    Desmin
    Gliofibrillary Acid Protein
    Neurofilaments
    Vimentin
    KA
    Kinases
    KP16D3
    LAI
    Leukocyte Common Antigen
    Lewis Antigens
    Lysophosphatidic Acid (LPA)
    Ma 695/Ma
    MABDF3
    MAG
    ME1
    Minactivin
    MN/CA9
    MSA
    Mucin Cancer Antigen (MCA)
    Multiple Tumor Suppressor
    Myosin
    NEA-130
    NMP22
    OA-519
    Opiod Peptides
    P-glycoprotein
    Pancreatic Oncofetal Antigen (POA)
    Placental Lactogen
    PR92
    Proliferative Index, Ki-67
    Px
    RB Inactivation/Deletion
    Ret
    SCCL
    Selectin
    Sialic Acid
    Sialyl SSEA-1/SLX
    SN10
    Somatostatin
    TA-90
    TABA
    Tachykinin
    TAG
    TPS
    Troponin
    Tubulin
    VCAM
    VEGF
    Villen and others

VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS

IX. CURRENT AND EMERGING TECHNOLOGIES

  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
  3. Molecular Diagnostics
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies

X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

XI. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
    Abbott
    Affymetrix
    Beckman Coulter/Danaher/Cepheid
    Becton Dickinson
    bioMerieux
    Bio-Rad
    DiaSorin
    Eiken Chemical
    Elitech Group
    Enzo Biochem
    Fuifilm Wako
    Fujirebio
    Grifols
    Hologic
    Leica Biosystems
    Ortho-Clinical Diagnostics
    PerkinElmer
    Qiagen
    Roche
    Siemens Healthineers
    Takara Bio
    Thermo Fisher and others.

List Of Tables

LIST OF TABLES

Cancer Diagnostic Test Volume and Sales Forecasts
Cancer Diagnostic Volume Forecast by Test
Cancer Diagnostics Sales Forecast by Test
ACTH Test Volume and Diagnostics Sales Forecast
AFP Test Volume and Diagnostics Sales Forecast
Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast
CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast
CA 19-9 Test Volume and Diagnostics Sales Forecast
CA-125 Test Volume and Diagnostics Sales Forecast
Calcitonin Test Volume and Diagnostics Sales Forecast
Cathepsin Test Volume and Diagnostics Sales Forecast
CEA Test Volume and Diagnostics Sales Forecast
Chromogranin Test Volume and Diagnostics Sales Forecast
Colon-specific Antigen Test Volume and Diagnostics Sales Forecast
Cytokeratins Test Volume and Diagnostics Sales Forecast
Estrogen Receptor Test Volume and Diagnostics Sales Forecast
Ferritin Test Volume and Diagnostics Sales Forecast
Gastrin Test Volume and Diagnostics Sales Forecast
HCG Test Volume and Diagnostics Sales Forecast
Insulin Test Volume and Diagnostics Sales Forecast
Interferons Test Volume and Diagnostics Sales
Interleukins Test Volume and Diagnostics Sales Forecast
Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast
NSE Test Volume and Diagnostics Sales Forecast
Nucleolar Test Volume and Diagnostics Sales Forecast
Occult Blood Test Volume and Diagnostics Sales Forecast
Oncogenes Test Volume and Diagnostics Sales Forecast
Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast
PAP Smear Test Volume and Diagnostics Sales Forecast Parathyroid
Hormone Test Volume and Diagnostics Sales Forecast Progesterone
Receptor Test Volume and Diagnostics Sales Forecast PAP Test Volume and Diagnostics Sales Forecast
PSA Test Volume and Diagnostics Sales Forecast
S-100 Protein Test Volume and Diagnostics Sales Forecast
Serotonin Test Volume and Diagnostics Sales Forecast
Sialic Acid Test Volume and Diagnostics Sales Forecast
Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast
TDT Test Volume and Diagnostics Sales Forecast
Thymidine Kinase Test Volume and Diagnostics Sales Forecast
Thyroglobulin Test Volume and Diagnostics Sales Forecast
TPA Test Volume and Diagnostics Sales Forecast
Cancer Diagnostic Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Sub-classification Tests
Biochemical Markers Potential Applications in Cancer Diagnosis
Oncogenes Potential Applications in Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications in Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications in Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis